Enhertu Receives 2026 International Prix Galien Award for Best Biotechnology Product Enhertu, a HER2-directed antibody drug conjugate (ADC) discovered by Daiichi Sankyo and jointly developed and commercialized by Daiichi Sankyo and AstraZeneca, has received the 2026 International Prix Galien Award…
Alkermes Initiates Phase 2 Study of ALKS 7290 as Adjunctive Treatment for Major Depressive Disorder Alkermes plc has announced the initiation of a Phase 2 clinical study evaluating ALKS 7290, an investigational orexin 2 receptor (OX2R) agonist, as an adjunctive…
Adjuvia Therapeutics Doses First Participant in Phase 1 Trial of ATI-105 for Friedreich’s Ataxia Adjuvia Therapeutics, a biotechnology company focused on developing novel treatments for mitochondrial dysfunction and associated diseases, has announced that the first participant has been dosed in…
Walmart Healthcare Research Institute and Care Access to Open Three New Clinical Trial Centers in 2027 Walmart Healthcare Research Institute (WHRI) and Care Access have announced plans to expand their community-based clinical research partnership with the opening of three additional…
Rumi Therapeutics Secures Option to License Enthorin’s IND-Ready PDE2 Inhibitor for Fragile X Syndrome Rumi Therapeutics, a drug-development company operating within Rumi Scientific Holdings, has announced an option-to-license agreement with Enthorin Therapeutics to advance RTX-7340, also known as ENT-7340, an…
Vertex Pharmaceuticals Reports Positive Phase 3 RAINIER Results for Povetacicept in IgA Nephropathy Published in NEJM Vertex Pharmaceuticals Incorporated has announced the publication of Phase 3 RAINIER trial results for povetacicept in the New England Journal of Medicine (NEJM), alongside…
TG Therapeutics Reports Initial Clinical Results for Azer-Cel CAR T-Cell Therapy in Progressive Multiple Sclerosis TG Therapeutics, Inc. has announced initial clinical results from its ongoing Phase 1 study evaluating azercabtagene zapreleucel (azer-cel), an investigational allogeneic CD19-directed chimeric antigen receptor…
BeOne Medicines Reports Longer-Term Survival Benefits for TEVIMBRA-Based Regimens in HER2-Positive Gastroesophageal Adenocarcinoma BeOne Medicines Ltd., a global oncology company, has announced new long-term survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase…
Salubris Biotherapeutics Presents Updated Phase 1b/2 Data for 5T4-Targeted ADC JK06 in Advanced Solid Tumors at ESMO 2026 Salubris Biotherapeutics, Inc., a clinical-stage biotechnology company focused on discovering and developing novel complex biologic therapeutics, has announced updated clinical data from…
Mundipharma Reports Additional Phase III ReSPECT Results Supporting REZZAYO for Invasive Fungal Disease Prevention After Stem Cell Transplantation Mundipharma has announced additional findings from the global Phase III ReSPECT clinical trial evaluating REZZAYO® (rezafungin acetate) for the prevention of invasive…
Drug Farm Reports Positive Preclinical Findings Showing DF-003 Reduces Kidney Inflammation and Fibrosis Drug Farm has announced positive preclinical findings demonstrating that DF-003, its proprietary, first-in-class oral ALPK1 inhibitor, reduced kidney inflammation and fibrosis in experimental models of chronic kidney…
Merck and Moderna Report Positive Phase 3 INTerpath-001 Results for Intismeran Autogene Plus KEYTRUDA in Resected Melanoma Merck, known as MSD outside the United States and Canada, and Moderna, Inc. (NASDAQ: MRNA) have announced detailed positive results from the Phase…